FDA Gives Green To Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Test


The FDA has approved Check-Cap Ltd's CHEK amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study of C-Scan.

  • The U.S. pivotal study consists of two parts. The first part is designed further to calibrate the system for the average risk U.S. population. 
  • The second part will include a statistically powered, randomized study that will compare C-Scan's performance to traditional colonoscopy.
  • The Company is focused on final preparations to initiate the first part of the U.S. pivotal study, anticipated to begin in March-April 2022, followed by initiation of the second part of the study in Q4 2022.
  • Related content: Benzinga's Full FDA Calendar.
  • C-Scan is the first and only patient-friendly preparation-free screening test to detect polyps before they might transform into colorectal cancer and enable early intervention and cancer prevention. 
  • C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, and proprietary software to generate a 3D map of the colon's inner lining as it travels naturally along the gastrointestinal tract. 
  • C-Scan is non-invasive and requires no sedation. 
  • Price Action: CHEK shares are trading 9.19% higher at $0.65 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!